



APIM THERAPEUTICS ANNOUNCES CLINICAL TRIAL APPLICATION APPROVAL FOR ITS FIRST-IN-CLASS DRUG, ATX-101

Trondheim, August 31st, 2018.

APIM Therapeutics announced today that a Clinical Trial Application (CTA) submitted by Therapim Pty Ltd, its fully owned subsidiary residing in Queensland, Australia, was accepted by Australian regulatory authorities. CTA approval will allow Therapim to initiate a multicenter, first-in-man phase I clinical trial evaluating the safety, tolerability and pharmacokinetics of ATX-101 in a total of 36 patients with advanced solid tumors.

ATX-101 is a first-in-class peptide drug targeting a novel therapeutic intervention point shown to be critical in the regulation of cellular responses to stress and in tumor evasion from therapy. Briefly, ATX-101 blocks protein-protein interactions between the master cell regulator PCNA (Proliferating Cell Nuclear Antigen) and a set of stress-related proteins containing a specific 5-amino acid PCNA-binding motif. Targeting this mechanism resulted in significant potentiation of the activity of a plethora of anti-cancer drugs in several preclinical blood and solid tumor cancer models.

“Achieving CTA approval is an extremely significant corporate milestone” stated Kostas Alevizopoulos, CEO of APIM Therapeutics. “We are excited to advance to clinical testing and are looking forward to evaluating the potential of ATX-101 to treat cancer in patients”.

Erlend Skagseth, Chairman of APIM Therapeutics and Managing Partner at Sarsia Seed (Lead investor), stated: “Approval of the CTA marks a significant milestone for APIM Therapeutics. We are delighted to be part of this program aiming to provide a novel therapeutic option to be tested in cancer patients”.

Based on current projections, the initial dosing of ATX-101 is expected to begin by late Q3 2018 with a target trial conclusion date estimated for late 2019 / early 2020.

About APIM Therapeutics

APIM Therapeutics is an early stage therapeutic company based on ground breaking research by Prof. Marit Otterlei and co-workers (Norwegian University of Science and Technology, NTNU, Trondheim, Norway). The company operates since 2009 and is financially backed up by an investor syndicate comprising, among others, Sarsia Seed, NIK III, Bergens Forskningsstiftelse and Investinor. The latest company transaction was concluded in Dec. 2017 (NOK 25M).

For further information, please contact:

APIM Therapeutics A/S
Kostas Alevizopoulos, CEO
e-mail: kalevizo@apimtherapeutics.com
www.apimtherapeutics.com